Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
281-300 of 936 trials

DZR123 for Advanced Solid Tumors and Lymphomas

We are studying a new treatment called DZR123 for patients with advanced solid tumors and lymphomas. The trial will help us understand its safety and how well it works alone and with another medication.

Advanced Solid Tumors and Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Acute Myeloid Leukemia: Vyxeos and Clofarabine Study

We are testing a new combination treatment for children with relapsed or refractory AML to find the best dose and evaluate its safety. The study aims to see if this treatment can help achieve remission and support future stem cell transplants.

Acute Myeloid LeukemiaSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

Colorectal Cancer: NILK-2301 Antibody Study

We are testing a new antibody treatment for patients with colorectal cancer to see how safe it is and how well it works. This study aims to gather important information for future treatments.

Locally Advanced or Metastatic Low Tumor Volume Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Solid Tumors: [177Lu]Lu-AKIR001 Treatment

We are testing a new treatment for adults with solid tumors that express CD44v6. The study aims to evaluate its safety and how well it works against these tumors.

Advanced Solid TumorsSafety phase (I)Oncology

Chronic Myeloid Leukemia: Asciminib for Kids

We are studying the safety and appropriate dose of asciminib in children with chronic myeloid leukemia. This research aims to ensure the medication is safe and effective for young patients who have already tried other treatments.

Philadelphia Positive Chronic Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

INBRX-109 for Advanced Solid Tumors, Including Sarcomas

We are studying a new treatment, INBRX-109, in combination with chemotherapy for adults and adolescents with advanced solid tumors like Ewing sarcoma and colorectal cancer. The goal is to assess its safety and how well it works compared to current treatments.

Advanced or Metastatic Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: RMC-6291 and RMC-6236 Combination Study

We are examining how well different doses of RMC-6291 and RMC-6236 are tolerated by people with advanced KRASG12C-mutated solid tumors. This study aims to gather important safety information about this treatment combination.

Non-Small Cell Lung CancerPancreatic AdenocarcinomaColorectal Cancer>2 yearsSafety phase (I)Oncology

Corticosteroids Detection in Anti-Doping Tests

We are studying how corticosteroids are excreted to improve their detection in anti-doping controls. This research aims to help ensure fair play in sports.

Healthy VolunteersSafety phase (I)Internal Medicine

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Severe Systemic Lupus Erythematosus: Obecabtagene Autoleucel Study

We are studying a new treatment for patients with severe, hard-to-treat systemic lupus erythematosus. The trial aims to evaluate its safety, tolerability, and early signs of effectiveness.

Severe Systemic Lupus ErythematosusSafety phase (I)No PlaceboInvestigational MedicinesInternal MedicineRheumatology

Primary Aldosteronism: [18F]CETO Imaging Study

We are investigating a new imaging method using [18F]CETO to better classify types of primary aldosteronism. This may help improve diagnosis and treatment for affected individuals.

Primary AldosteronismSafety phase (I)Efficacy phase (II)EndocrinologyInternal Medicine

Liver Transplant: Regulatory T Cell Therapy

We are studying a new treatment using regulatory T cells for liver transplant recipients to see if it is safe and allows them to stop taking tacrolimus. We also want to learn how it affects graft function and patients' quality of life.

Liver TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: AZD0901 Treatment Study

We are investigating the safety and effectiveness of AZD0901, alone or with other cancer drugs, for patients with advanced solid tumors expressing Claudin 18.2. This study aims to understand how well this treatment may work and its potential side effects.

Gastric CancerGastroesophageal Junction CancerPancreatic Ductal AdenocarcinomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Recurrent Glioblastoma: Ipilimumab and Nivolumab Treatment

We are testing a new combination of two immunotherapy drugs for patients with recurrent glioblastoma. The goal is to see if this approach improves treatment outcomes compared to standard options.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

NBI-1076986: Safety and Effects in Healthy Adults

We are studying a new medication to see how safe it is and how the body reacts to it in healthy adults. This research helps us understand its potential for future use in patients.

Movement Disorders>2 yearsSafety phase (I)Neurology

Non-Small Cell Lung Cancer: Furmonertinib Study

We are evaluating the safety and effectiveness of Furmonertinib for patients with non-small cell lung cancer who have specific EGFR or HER2 mutations. This study aims to see how well the drug works in treating this type of cancer.

Non-Small Cell Lung Cancer (NSCLC)Safety phase (I)OncologyPulmonology

Relapsed/Refractory T-Cell Leukemia: CD7 CAR T-Cell Therapy

We are testing a new type of T-cell therapy for children and young adults with relapsed or refractory T-cell leukemia or lymphoma. The study aims to find a safe dose and see how well it works.

T-cell Acute Lymphoblastic Leukemia/Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Early-Onset Alzheimer's Disease: ALN-APP Treatment

We are evaluating the safety and tolerability of a new treatment called ALN-APP for patients with early-onset Alzheimer's disease. This study aims to understand how well the treatment is tolerated in humans.

Early-onset Alzheimer's DiseaseSafety phase (I)Neurology

Inflammatory Bowel Disease: Adalimumab-680LT Study

We are investigating the safety and imaging of a new version of adalimumab for people with inflammatory bowel diseases. This study aims to see how well the drug targets inflammation and its potential effects on health.

Inflammatory Bowel Disease (IBD)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases